-
The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells
Cory T. Zumbar, Aisulu Usubalieva, Paul D. King, Xiaohui Li, Caroline S. Mifsud, Hailey M. Dalton, Muge Sak, Sara Urio, William
M. Bryant, Joseph P. McElroy, George Farmer, and Norman L. Lehman
Journal of Neuro-Oncology
(2018)
137 :481
-
Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
T. J. Mitchison, J. Pineda, J. Shi, and S. Florian
Open Biology
(2017)
7 :170182
-
Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer
properties
Pauline Gilson, Fernando Josa-Prado, Claire Beauvineau, Delphine Naud-Martin, Laetitia Vanwonterghem, Florence Mahuteau-Betzer,
Alexis Moreno, Pierre Falson, Laurence Lafanechère, Véronique Frachet, Jean-Luc Coll, Jose Fernando Díaz, Amandine Hurbin,
and Benoit Busser
Scientific Reports
(2017)
7 :
-
Characterization of a highly selective inhibitor of the Aurora kinases
Fleur M. Ferguson, Zainab M. Doctor, Apirat Chaikuad, Taebo Sim, Nam Doo Kim, Stefan Knapp, and Nathanael S. Gray
Bioorganic & Medicinal Chemistry Letters
(2017)
27 :4405
-
50 years on … the discovery of tubulin continues to advance cancer treatment
Karen Crasta and Ritu Aneja
Endocrine-Related Cancer
(2017)
24 :E3
-
Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
Alexander Lorz, Dana-Adriana Botesteanu, and Doron Levy
Scientific Reports
(2018)
8 :
-
Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
Alexander Lorz, Dana-Adriana Botesteanu, and Doron Levy
Frontiers in Oncology
(2017)
7 :
